Nasal polyps
Drug research and approvals for nasal polyps: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 43 studies of nasal polyps are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 43
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 1
- Metabolic and Immunologic Biomarkers in Chronic Rhinosinusitis With Nasal PolypsNCT07860411 · Not reported · Harran University · starts Mar 15, 2026
- Mepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS).NCT07814924 · Phase 4 · Instituto de Investigación Marqués de Valdecilla · starts Dec 31, 2024
- A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis…NCT07782970 · Phase 3 · GlaxoSmithKline · starts Sep 28, 2026
- A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With…NCT07782957 · Phase 3 · GlaxoSmithKline · starts Sep 3, 2026
- Triamcinolone Nanocapsules After Endoscopic Nasal SurgeryNCT07714525 · Phase 2 · Deraya University · starts May 1, 2026
- Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese…NCT07701967 · Phase 4 · GlaxoSmithKline · starts Jul 15, 2026
- Cognitive and Immunologic Profiles of Patients With Olfactory Dysfunction After Smell TrainingNCT07681973 · Not applicable · The Cleveland Clinic · starts Dec 9, 2025
- Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and…NCT07633158 · Not reported · AstraZeneca · starts Jun 10, 2026
- A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With TezepelumabNCT07520162 · Phase 3 · AstraZeneca · starts Apr 24, 2026
Approved 3
- Mometasone furoateGlucocorticoid receptor agonist
- Fluticasone propionateGlucocorticoid receptor agonist
- DupilumabInterleukin-4 receptor subunit alpha antagonist
Phase 3 6
- BenralizumabInterleukin-5 receptor subunit alpha inhibitor
- MepolizumabInterleukin-5 inhibitor
- DepemokimabInterleukin-5 inhibitor
- Tranexamic acidPlasminogen inhibitor
- PrednisoneGlucocorticoid receptor agonist
- FevipiprantG protein-coupled receptor 44 antagonist
Phase 2 5
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- FurosemideSodium-(potassium)-chloride cotransporter 2 inhibitor
- BudesonideGlucocorticoid receptor agonist
- Beclomethasone dipropionateGlucocorticoid receptor agonist
- ACT-774312
Phase 1 or earlier 3
- TriamcinoloneGlucocorticoid receptor agonist
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- DexmedetomidineAdrenergic receptor alpha-2 agonist
How its trials ended
230 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 48 whose ending is known, 48% met their primary endpoint, 4% missed it and 48% stopped early.
- Ongoing7733%
- Completed, result not reported7432%
- Status unknown3113%
- Met its primary endpoint2310%
- Stopped: other or unclear125%
- Stopped: enrollment or feasibility63%
- Stopped: lack of efficacy31%
- Missed its primary endpoint21%
- Stopped: sponsor or business decision1<1%
- Stopped: funding1<1%
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Dec 1, 2015 | NucalaMepolizumab | GlaxoSmithKline Trading Services Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA